Design and evaluation of a multi-epitope DNA vaccine against HPV16

References

• Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):191–18. doi:10.1016/S2214-109X(19)30482-6.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Clarke M, Nelson C, Dean M, Wentzensen N, Yeager M, Cullen M, Boland J, Schiffman M, Burk R, et al. The intersection of HPV epidemiology, genomics and mechanistic studies of HPV-mediated carcinogenesis. Viruses. 2018;10(2):80. doi:10.3390/v10020080.
   PubMed Web of Science ®Google Scholar
• Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32):4768–73. doi:10.1016/j.vaccine.2017.12.079.
   PubMed Web of Science ®Google Scholar
• Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, Gao C, Ma D, Liao S. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88–102. doi:10.1016/j.canlet.2019.11.039.
   PubMed Web of Science ®Google Scholar
• Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23. doi:10.1002/rmv.1822.
   PubMed Web of Science ®Google Scholar
• Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007;98(10):1505–11. doi:10.1111/j.1349-7006.2007.00546.x.
   PubMed Web of Science ®Google Scholar
• Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, Weiner DB, Sewell D. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine. 2009;27(3):431–40. doi:10.1016/j.vaccine.2008.10.078.
   PubMed Web of Science ®Google Scholar
• Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, et al. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016;65(5):563–73. doi:10.1007/s00262-016-1821-x.
   PubMed Web of Science ®Google Scholar
• Alvarez RD, Huh WK, Bae S, Lamb LS, Conner MG, Boyer J, Wang C, Hung C-F, Sauter E, Paradis M, et al. A pilot study of pNgvl4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol. 2016;140(2):245–52. doi:10.1016/j.ygyno.2015.11.026.
   PubMed Web of Science ®Google Scholar
• Dupont J, Latouche JB, Ma C, Sadelain M. Artificial Antigen-Presenting Cells Transduced with telomerase efficiently expand epitope-specific, human leukocyte Antigen–restricted cytotoxic T Cells. Cancer Res. 2005;65(12):5417–27. doi:10.1158/0008-5472.CAN-04-2991.
   PubMed Web of Science ®Google Scholar
• Hernandez J, García-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A. 2002;99(19):12275–80. doi:10.1073/pnas.182418399.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol. 2000;164(7):3902–12. doi:10.4049/jimmunol.164.7.3902.
   PubMed Web of Science ®Google Scholar
• Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BWS, Scott B. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol. 2000;165(11):6047–55. doi:10.4049/jimmunol.165.11.6047.
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188(12):2357–68. doi:10.1084/jem.188.12.2357.
   PubMed Web of Science ®Google Scholar
• Khalid H, Ashfaq UA. Exploring HCV genome to construct multi-epitope based subunit vaccine to battle HCV infection: immunoinformatics based approach. J Biomed Inform. 2020;108:103498. doi:10.1016/j.jbi.2020.103498.
   PubMed Web of Science ®Google Scholar
• Yu M, Zhu Y, Li Y, Chen Z, Li Z, Wang J, Li Z, Zhang F, Ding J. Design of a recombinant multivalent epitope vaccine based on SARS-CoV-2 and its variants in immunoinformatics approaches. Front Immunol. 2022;13:884433. doi:10.3389/fimmu.2022.884433.
   PubMed Web of Science ®Google Scholar
• Cheng P, Wang L, Gong W. In silico analysis of peptide-based biomarkers for the diagnosis and prevention of latent tuberculosis infection. Front Microbiol. 2022;13:947852. doi:10.3389/fmicb.2022.947852.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445–50. doi:10.1016/s1369-5274(00)00119-3.
   PubMed Web of Science ®Google Scholar
• Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S, Nielsen M. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2009;61(1):1–13. doi:10.1007/s00251-008-0341-z.
   PubMed Web of Science ®Google Scholar
• Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):449–54. doi:10.1093/nar/gkaa379.
   PubMed Web of Science ®Google Scholar
• Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010;11(1):568. doi:10.1186/1471-2105-11-568.
   PubMed Web of Science ®Google Scholar
• Doytchinova IA, Flower DR. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. Vaccine. 2007;25(5):856–66. doi:10.1016/j.vaccine.2006.09.032.
   PubMed Web of Science ®Google Scholar
• Dhanda SK, Vir P, Raghava GP. Designing of interferon-gamma inducing MHC class-II binders. Biol Direct. 2013;8(1):30. doi:10.1186/1745-6150-8-30.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GPS. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8(9):e73957. doi:10.1371/journal.pone.0073957.
   PubMed Web of Science ®Google Scholar
• Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinf. 2006;7(1):153. doi:10.1186/1471-2105-7-153.
   PubMed Web of Science ®Google Scholar
• Zheng W, Zhang C, Li Y, Pearce R, Bell EW, Zhang Y. Folding non-homologous proteins by coupling deep-learning contact maps with I-TASSER assembly simulations. Cell Rep Methods. 2021;1(3):100014. doi:10.1016/j.crmeth.2021.100014.
   PubMedGoogle Scholar
• Desta IT, Porter KA, Xia B, Kozakov D, Vajda S. Performance and its limits in rigid body protein-protein docking. Structure. 2020;28(9):1071–81 e1073. doi:10.1016/j.str.2020.06.006.
   PubMed Web of Science ®Google Scholar
• Rahmani A, Baee M, Rostamtabar M, Karkhah A, Alizadeh S, Tourani M, Nouri HR. Development of a conserved chimeric vaccine based on helper T-cell and CTL epitopes for induction of strong immune response against schistosoma mansoni using immunoinformatics approaches. Int J Biol Macromol. 2019;141:125–36. doi:10.1016/j.ijbiomac.2019.08.259.
   PubMed Web of Science ®Google Scholar
• Honorato RV, Koukos PI, Jiménez-García B, Tsaregorodtsev A, Verlato M, Giachetti A, Rosato A, Bonvin AMJJ. Structural biology in the clouds: the WeNMR-EOSC Ecosystem. Front Mol Biosci. 2021;8:729513. doi:10.3389/fmolb.2021.729513.
   PubMed Web of Science ®Google Scholar
• Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, Sette A. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol. 2002;168(11):5499–506. doi:10.4049/jimmunol.168.11.5499.
   PubMed Web of Science ®Google Scholar
• Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 2001;14(8):529–32. doi:10.1093/protein/14.8.529.
   PubMedGoogle Scholar
• Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 1999;112:531–52. doi:10.1385/1-59259-584-7:531.
   PubMedGoogle Scholar
• Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2—a server for in silico prediction of allergens. J Mol Model. 2014;20(6):2278. doi:10.1007/s00894-014-2278-5.
   PubMed Web of Science ®Google Scholar
• Hebditch M, Carballo-Amador MA, Charonis S, Curtis R, Warwicker J, Valencia A. Protein–sol: a web tool for predicting protein solubility from sequence. Bioinformatics. 2017;33(19):3098–100. doi:10.1093/bioinformatics/btx345.
   PubMed Web of Science ®Google Scholar
• Laskowski RA, Jablonska J, Pravda L, Varekova RS, Thornton JM. Pdbsum: structural summaries of PDB entries. Protein Sci. 2018;27(1):129–34. doi:10.1002/pro.3289.
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–9. doi:10.1038/s41586-021-03819-2.
   PubMed Web of Science ®Google Scholar
• Seok C, Baek M, Steinegger M, Park H, Lee GR, Won J. Accurate protein structure prediction: what comes next? Biodesign. 2021;9(3):47–50. doi:10.34184/kssb.2021.9.3.47.
   Google Scholar
• Laskowski RA. PDBsum1: a standalone program for generating PDBsum analyses. Protein Sci. 2022;31(12):e4473. doi:10.1002/pro.4473.
   PubMed Web of Science ®Google Scholar
• Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(Web Server):W407–410. doi:10.1093/nar/gkm290.
   PubMed Web of Science ®Google Scholar
• Lopez-Blanco JR, Aliaga JI, Quintana-Orti ES, Chacon P. iMODS: internal coordinates normal mode analysis server. Nucleic Acids Res. 2014;42(W1):W271–276. doi:10.1093/nar/gku339.
   PubMed Web of Science ®Google Scholar
• Rapin N, Lund O, Bernaschi M, Castiglione F, Brusic V. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS One. 2010;5(4):e9862. doi:10.1371/journal.pone.0009862.
   PubMed Web of Science ®Google Scholar
• Grote A, Hiller K, Scheer M, Munch R, Nortemann B, Hempel DC, Jahn D. Jcat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005;33:W526–531. doi:10.1093/nar/gki376.
   PubMed Web of Science ®Google Scholar
• Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21–6.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, Røder G, Peters B, Sette A, Lund O, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One. 2007;2(8):e796. doi:10.1371/journal.pone.0000796.
   PubMed Web of Science ®Google Scholar
• Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360–8. doi:10.4049/jimmunol.1700893.
   PubMed Web of Science ®Google Scholar
• Eberhardt CS, Kissick HT, Patel MR, Cardenas MA, Prokhnevska N, Obeng RC, Nasti TH, Griffith CC, Im SJ, Wang X, et al. Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer. Nature. 2021;597(7875):279–84. doi:10.1038/s41586-021-03862-z.
   PubMed Web of Science ®Google Scholar
• Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol. 2008;15(6):937–45. doi:10.1128/CVI.00404-07.
   PubMedGoogle Scholar
• Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, Saito T, Sato N. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses. Exp Mol Pathol. 2012;92(1):185–90. doi:10.1016/j.yexmp.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Morishima S, Akatsuka Y, Nawa A, Kondo E, Kiyono T, Torikai H, Nakanishi T, Ito Y, Tsujimura K, Iwata K, et al. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-γ on the presentation of a cryptic epitope. Int J Cancer. 2007;120(3):594–604. doi:10.1002/ijc.22312.
   PubMed Web of Science ®Google Scholar
• He X, Zhou S, Quinn B, Jahagirdar D, Ortega J, Abrams SI, Lovell JF. HPV-Associated tumor eradication by vaccination with synthetic short peptides and particle-forming liposomes. Small. 2021;17(11):e2007165. doi:10.1002/smll.202007165.
   PubMed Web of Science ®Google Scholar
• Kruse S, Büchler M, Uhl P, Sauter M, Scherer P, Lan TCT, Zottnick S, Klevenz A, Yang R, Rösl F, et al. Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model. Oncoimmunology. 2019;8(1):e1524694. doi:10.1080/2162402X.2018.1524694.
   PubMed Web of Science ®Google Scholar
• Blatnik R, Mohan N, Bonsack M, Falkenby LG, Hoppe S, Josef K, Steinbach A, Becker S, Nadler WM, Rucevic M, et al. A targeted LC-MS strategy for low-abundant HLA class-I-Presented peptide detection identifies novel human papillomavirus T-Cell Epitopes. Proteomics. 2018;18(11):e1700390. doi:10.1002/pmic.201700390.
   PubMed Web of Science ®Google Scholar
• Firdaus FZ, Bartlett S, Hussein WM, Lu L, Wright Q, Huang W, Nahar UJ, Yang J, Khongkow M, Veitch M, et al. Liposomal formulations of a polyleucine–antigen conjugate as therapeutic vaccines against cervical cancer. Pharmaceutics. 2023;15(2):602. doi:10.3390/pharmaceutics15020602.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ren F, Ni B, Jing T, Tang J. Tumor targeting nanoparticle E7 49-57 -HSP110-RGD elicits potent anti-tumor immune response in a CD8-dependent manner in cervical cancer-bearing mouse model. Hum Vaccin Immunother. 2021;17(10):3529–38. doi:10.1080/21645515.2021.1933875.
   PubMed Web of Science ®Google Scholar
• Goradel NH, Negahdari B, Mohajel N, Malekshahi ZV, Shirazi MMA, Arashkia A. Heterologous administration of HPV16 E7 epitope-loaded nanocomplexes inhibits tumor growth in mouse model. Int Immunopharmacol. 2021;101:108298. doi:10.1016/j.intimp.2021.108298.
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Newman MJ, deCamp A, Hay CM, De Rosa SC, Noonan E, Livingston BD, Fuchs JD, Kalams SA, Cassis-Ghavami FL, et al. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin Vaccine Immunol. 2012;19(5):649–58. doi:10.1128/CVI.00038-12.
   PubMedGoogle Scholar
• Cheng WF, Hung C-F, Chai C-Y, Hsu K-F, He L, Ling M, Wu T-C. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108(5):669–78. doi:10.1172/JCI12346.
   PubMed Web of Science ®Google Scholar
• Kim JW, Hung C-F, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen P-J, Lin C-T, Boyd DA, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 2004;11(12):1011–18. doi:10.1038/sj.gt.3302252.
   PubMed Web of Science ®Google Scholar
• Peng S, Ji H, Trimble C, He L, Tsai Y-C, Yeatermeyer J, Boyd DAK, Hung C-F, Wu T-C. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol. 2004;78(16):8468–76. doi:10.1128/JVI.78.16.8468-8476.2004.
   PubMed Web of Science ®Google Scholar
• Waqas M, Aziz S, Bushra A, Halim SA, Ali A, Ullah S, Khalid A, Abdalla AN, Khan A, Al-Harrasi A, et al. Employing an immunoinformatics approach revealed potent multi-epitope based subunit vaccine for lymphocytic choriomeningitis virus. J Infect Public Health. 2023;16(2):214–32. doi:10.1016/j.jiph.2022.12.023.
   PubMed Web of Science ®Google Scholar
• Tarrahimofrad H, Zamani J, Hamblin MR, Darvish M, Mirzaei H. A designed peptide-based vaccine to combat Brucella melitensis, B. suis and B. abortus: harnessing an epitope mapping and immunoinformatics approach. Biomed Pharmacother. 2022;155:113557. doi:10.1016/j.biopha.2022.113557.
   PubMed Web of Science ®Google Scholar
• Lei Y, Zhao F, Shao J, Li Y, Li S, Chang H, Zhang Y. Application of built-in adjuvants for epitope-based vaccines. PeerJ. 2019;6:e6185. doi:10.7717/peerj.6185.
   PubMed Web of Science ®Google Scholar
• Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 2000;60:1035–42.
   PubMed Web of Science ®Google Scholar
• Lasaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes Infect. 2005;7(15):1541–50. doi:10.1016/j.micinf.2005.05.024.
   PubMed Web of Science ®Google Scholar
• Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF. Human β-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci U S A. 2007;104(47):18631–5. doi:10.1073/pnas.0702130104.
   PubMed Web of Science ®Google Scholar
• Peng S, Ferrall L, Gaillard S, Wang C, Chi W-Y, Huang C-H, Roden RBS, Wu T-C, Chang Y-N, Hung C-F, et al. Development of D,A vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody. mBio. 2021;12(1). doi:10.1128/mBio.03224-20.
   Web of Science ®Google Scholar
• Sarkar B, Ullah MA, Araf Y. A systematic and reverse vaccinology approach to design novel subunit vaccines against Dengue virus type-1 (DENV-1) and human papillomavirus-16 (HPV-16). Inform Med Unlocked. 2020;19:100343. doi:10.1016/j.imu.2020.100343.
   Google Scholar
• Negahdaripour M, Eslami M, Nezafat N, Hajighahramani N, Ghoshoon MB, Shoolian E, Dehshahri A, Erfani N, Morowvat MH, Ghasemi Y, et al. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches. Infect Genet Evol. 2017;54:402–16. doi:10.1016/j.meegid.2017.08.002.
   PubMed Web of Science ®Google Scholar
• Sanami S, Azadegan-Dehkordi F, Rafieian-Kopaei M, Salehi M, Ghasemi-Dehnoo M, Mahooti M, Alizadeh M, Bagheri N. Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches. Sci Rep. 2021;11(1):12397. doi:10.1038/s41598-021-91997-4.
   PubMed Web of Science ®Google Scholar
• Wang Y, Weng Y, Shi Y, Xia X, Wang S, Duan H. Expression and functional analysis of Toll-like receptor 4 in human cervical carcinoma. J Membr Biol. 2014;247(7):591–9. doi:10.1007/s00232-014-9675-7.
   PubMed Web of Science ®Google Scholar
• Hashimoto C, Hudson KL, Anderson KV. The toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988;52(2):269–79. doi:10.1016/0092-8674(88)90516-8.
   PubMed Web of Science ®Google Scholar
• Omoboyede V, Ibrahim O, Umar HI, Bello T, Adedeji AA, Khalid A, Fayojegbe ES, Ayomide AB, Chukwuemeka PO. Designing a vaccine-based therapy against Epstein-Barr virus-associated tumors using immunoinformatics approach. Comput Biol Med. 2022;150:106128. doi:10.1016/j.compbiomed.2022.106128.
   PubMed Web of Science ®Google Scholar
• Pritam M, Singh G, Swaroop S, Singh AK, Pandey B, Singh SP. A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria. Int J Biol Macromol. 2020;158:159–79. doi:10.1016/j.ijbiomac.2020.04.191.
   PubMed Web of Science ®Google Scholar
• Cheng P, Xue Y, Wang J, Jia Z, Wang L, Gong W. Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT. Front Cell Infect Microbiol. 2022;12:1047306. doi:10.3389/fcimb.2022.1047306.
   PubMed Web of Science ®Google Scholar
• Andongma BT, Huang Y, Chen F, Tang Q, Yang M, Chou S-H, Li X, He J. In silico design of a promiscuous chimeric multi-epitope vaccine against mycobacterium tuberculosis. Comput Struct Biotechnol J. 2023;21:991–1004. doi:10.1016/j.csbj.2023.01.019.
   PubMed Web of Science ®Google Scholar
• Peng S, Tu H-F, Cheng M, Hu M-H, Tsai H-L, Tsai Y-C, Koenig C, Brayton C, Wang H, Chang Y-N, et al. Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector. mBio. 2023;14(5):e0212123. doi:10.1128/mbio.02121-23.
   PubMed Web of Science ®Google Scholar
• Zuo W, Li J, Jiang W, Zhang M, Ma Y, Gu Q, Wang X, Cai L, Shi L, Sun M, et al. Dose-sparing intradermal DTaP-sIPV immunization with a hollow microneedle leads to Superior immune responses. Front Microbiol. 2021;12:757375. doi:10.3389/fmicb.2021.757375.
   PubMed Web of Science ®Google Scholar
• Porchia B, Moreno ACR, Ramos RN, Diniz MO, de Andrade LHTM, Rosa DS, Barbuto JAM, Boscardin SB, Ferreira LCS. Herpes simplex virus glycoprotein D targets a specific dendritic cell subset and improves the performance of vaccines to human papillomavirus-associated tumors. Mol Cancer Ther. 2017;16(9):1922–33. doi:10.1158/1535-7163.MCT-17-0071.
   PubMed Web of Science ®Google Scholar
• Ramos da Silva J, Ramos Moreno AC, Silva Sales N, de Oliveira Silva M, Aps LRMM, Porchia BFMM, Bitencourt Rodrigues K, Cestari Moreno N, Venceslau-Carvalho AA, Menck CFM, et al. A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate HPV-associated tumors in a preclinical model. Oncoimmunology. 2021;10(1):1949896. doi:10.1080/2162402X.2021.1949896.
   PubMed Web of Science ®Google Scholar
• Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L, Lin CT, Wu T-C. CD8+ T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther. 2003;10(16):1311–20. doi:10.1038/sj.gt.3301982.
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003;300(5617):337–9. doi:10.1126/science.1082305.
   PubMed Web of Science ®Google Scholar
• Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300(5617):339–42. doi:10.1126/science.1083317.
   PubMed Web of Science ®Google Scholar
• Han X, Gao Z, Cheng Y, Wu S, Chen J, Zhang W. A therapeutic DNA vaccine targeting HPV16 E7 in combination with anti-PD-1/PD-L1 enhanced tumor regression and cytotoxic immune responses. Int J Mol Sci. 2023;24(20):15469. doi:10.3390/ijms242015469.
   PubMed Web of Science ®Google Scholar
• Kayyal M, Bolhassani A, Noormohammadi Z, Sadeghizadeh M. In silico design and immunological studies of two novel multiepitope DNA-Based vaccine candidates against high-risk human papillomaviruses. Mol Biotechnol. 2021;63(12):1192–222. doi:10.1007/s12033-021-00374-z.
   PubMed Web of Science ®Google Scholar
• Qi W, Qingfeng L, Jing Z, Maolin Z, Zhihui Z, Wangqi D, Shanli Z, Jun C, Pengfei J, Lifang Z, et al. A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model. Vaccine. 2022;40(52):7693–702. doi:10.1016/j.vaccine.2022.10.069.
   PubMed Web of Science ®Google Scholar